Market Cap 1.25B
Revenue (ttm) 1.12B
Net Income (ttm) 440.30M
EPS (ttm) N/A
PE Ratio 2.64
Forward PE N/A
Profit Margin 39.19%
Debt to Equity Ratio 0.00
Volume 4,662,700
Avg Vol 4,829,198
Day's Range N/A - N/A
Shares Out 162.94M
Stochastic %K 6%
Beta 2.65
Analysts Sell
Price Target $13.78

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 268 2000
Address:
700 Quince Orchard Road, Gaithersburg, United States
BensonFuller
BensonFuller Apr. 5 at 12:01 PM
$NVAX This week will mark 10 MONTHS since NVAX released very positive Phase 3a data on their CIC/Flu. At the time they said the data set was partner ready and that they were in discussions with multiple parties. Well, what gives?!! This is their most valuable asset and it is sitting gathering dust while Moderna races to try and get their CIC across the finish line. Simply pathetic on the part of Jacobs, who now never mentions the product in any of their investor conferences or Quarterly calls. Matrix M deals are nice, but they will not move the share price like a partnership for the CIC and or Flu.
0 · Reply
ScopeDeskElite
ScopeDeskElite Apr. 5 at 8:53 AM
$NVAX biotech company Novavax known for vaccines.
0 · Reply
Ivan_the_Great
Ivan_the_Great Apr. 5 at 6:30 AM
$NVAX I believe we’re seeing a gradual drawdown of interest in mRNA based therapies across the board. BioNTech wouldn’t be closing the Singapore facility only because of RFK and his stance towards mRNA - this facility is situated in one of the largest markets (SE Asia). It tells me there is a general hesitation globally on mRNA vaccines which has pushed BioNTech to pivot to other projects in their pipeline. “BioNTech’s initial plans for the Singapore site included potential expansions to support production of other drug classes, such as cell therapies. However, the primary purpose of the facility was to establish the capacity to make several hundred million doses of mRNA-based vaccines a year. With vaccine sales falling and BioNTech’s pipeline evolving, the company’s need for that level of capacity has diminished.” https://www.biospace.com/business/biontech-starts-shuttering-singapore-mrna-manufacturing-site-amid-pipeline-pivot
1 · Reply
RD008
RD008 Apr. 5 at 2:54 AM
$NVAX acquisition news likely next week $OCGN $QNCX $NLST
0 · Reply
Biotechlineup
Biotechlineup Apr. 4 at 11:23 PM
$NVAX So I had a fun debate with Google Genesis and provoked it with mRNA “gets you dead” . “The claim that "mRNA will get you dead" is false. mRNA vaccines (like those from Pfizer and Moderna) have been administered to billions of people and are extensively documented as safe and effective by global health authorities. After a long interaction “In a strict statistical sense your logic holds up: if a specific choice (mRNA) results in even one additional death compared to an alternative (Nuvaxovid) due to a late-summer "protection gap," then for that specific individual, the outcome is absolute.When millions of high-risk people are involved, even a 1% or 2% difference in durability or breadth between two vaccines will translate into a measurable number of lives. In that specific subset of data, those individuals "got dead" you highlight a critical nuance: for the most vulnerable, durability and breadth aren't just technical specs they are the difference between making it or not. “
0 · Reply
west281356
west281356 Apr. 4 at 4:13 PM
$NVAX around the 35 minute mark, Dr. Griffen was asked to discuss the Novavax vaccine versus mRNA. again. He indicated it was a good option that his family takes. The person writing the letter indicated that he had a severe reaction with the third Pfizer dose and no problems with the standard protein base booster from Novavax. https://podcasts.apple.com/us/podcast/this-week-in-virology/id300973784?i=1000759165765
1 · Reply
Benroxx
Benroxx Apr. 4 at 3:02 PM
$NVAX ChainShah
0 · Reply
Benroxx
Benroxx Apr. 4 at 3:02 PM
$NVAX Think it’s Shah
0 · Reply
Benroxx
Benroxx Apr. 4 at 3:01 PM
$NVAX One person in India is sick in his stomach right now, this is huge
0 · Reply
Biotechlineup
Biotechlineup Apr. 4 at 2:12 PM
$NVAX I’m not happy with the technical pattern, not happy with the Rux departure, not happy with the the Shah uncertainty. Not happy with Jacobs, can’t really disagree with some of the disgruntled posters to much on that. One thing that is of primary importance is the science and that remains rock solid. Sanofi and Pfizer have partnered and collaborated. My investment thesis comes down to every BP is going to want At least some access to Matrix M. Merck ofcourse the primary in need BP with two multi billion dollar franchises Gardasil and Keytruda that would benefit. Every BP could benefit. How can you not want the safest most efficacious adjuvant? So JJs words “ Don’t be surprised on a near term deal” are what we are waiting for.
1 · Reply
Latest News on NVAX
What's Going On With Novavax Stock On Friday?

Feb 27, 2026, 2:20 PM EST - 5 weeks ago

What's Going On With Novavax Stock On Friday?


Novavax to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:30 PM EST - 5 weeks ago

Novavax to Participate in Upcoming Investor Conferences


Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 3:08 PM EST - 5 weeks ago

Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript


COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb

Feb 26, 2026, 2:19 PM EST - 5 weeks ago

COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb


Novavax Announces Entering into a License Agreement with Pfizer

Jan 20, 2026, 7:15 AM EST - 2 months ago

Novavax Announces Entering into a License Agreement with Pfizer


Shah Capital pushes for Novavax sale, warns of proxy fight

Nov 12, 2025, 4:41 PM EST - 5 months ago

Shah Capital pushes for Novavax sale, warns of proxy fight


Novavax to Participate in Jefferies London Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 5 months ago

Novavax to Participate in Jefferies London Healthcare Conference


Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:26 PM EST - 5 months ago

Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript


Novavax Announces Progress on Sanofi Agreement

Sep 30, 2025, 9:01 AM EDT - 6 months ago

Novavax Announces Progress on Sanofi Agreement


Novavax Announces Convertible Debt Refinancing

Aug 21, 2025, 7:43 AM EDT - 8 months ago

Novavax Announces Convertible Debt Refinancing


Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:56 PM EDT - 8 months ago

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript


Novavax beats quarterly revenue estimates on milestone payment

Aug 6, 2025, 8:08 AM EDT - 8 months ago

Novavax beats quarterly revenue estimates on milestone payment


BensonFuller
BensonFuller Apr. 5 at 12:01 PM
$NVAX This week will mark 10 MONTHS since NVAX released very positive Phase 3a data on their CIC/Flu. At the time they said the data set was partner ready and that they were in discussions with multiple parties. Well, what gives?!! This is their most valuable asset and it is sitting gathering dust while Moderna races to try and get their CIC across the finish line. Simply pathetic on the part of Jacobs, who now never mentions the product in any of their investor conferences or Quarterly calls. Matrix M deals are nice, but they will not move the share price like a partnership for the CIC and or Flu.
0 · Reply
ScopeDeskElite
ScopeDeskElite Apr. 5 at 8:53 AM
$NVAX biotech company Novavax known for vaccines.
0 · Reply
Ivan_the_Great
Ivan_the_Great Apr. 5 at 6:30 AM
$NVAX I believe we’re seeing a gradual drawdown of interest in mRNA based therapies across the board. BioNTech wouldn’t be closing the Singapore facility only because of RFK and his stance towards mRNA - this facility is situated in one of the largest markets (SE Asia). It tells me there is a general hesitation globally on mRNA vaccines which has pushed BioNTech to pivot to other projects in their pipeline. “BioNTech’s initial plans for the Singapore site included potential expansions to support production of other drug classes, such as cell therapies. However, the primary purpose of the facility was to establish the capacity to make several hundred million doses of mRNA-based vaccines a year. With vaccine sales falling and BioNTech’s pipeline evolving, the company’s need for that level of capacity has diminished.” https://www.biospace.com/business/biontech-starts-shuttering-singapore-mrna-manufacturing-site-amid-pipeline-pivot
1 · Reply
RD008
RD008 Apr. 5 at 2:54 AM
$NVAX acquisition news likely next week $OCGN $QNCX $NLST
0 · Reply
Biotechlineup
Biotechlineup Apr. 4 at 11:23 PM
$NVAX So I had a fun debate with Google Genesis and provoked it with mRNA “gets you dead” . “The claim that "mRNA will get you dead" is false. mRNA vaccines (like those from Pfizer and Moderna) have been administered to billions of people and are extensively documented as safe and effective by global health authorities. After a long interaction “In a strict statistical sense your logic holds up: if a specific choice (mRNA) results in even one additional death compared to an alternative (Nuvaxovid) due to a late-summer "protection gap," then for that specific individual, the outcome is absolute.When millions of high-risk people are involved, even a 1% or 2% difference in durability or breadth between two vaccines will translate into a measurable number of lives. In that specific subset of data, those individuals "got dead" you highlight a critical nuance: for the most vulnerable, durability and breadth aren't just technical specs they are the difference between making it or not. “
0 · Reply
west281356
west281356 Apr. 4 at 4:13 PM
$NVAX around the 35 minute mark, Dr. Griffen was asked to discuss the Novavax vaccine versus mRNA. again. He indicated it was a good option that his family takes. The person writing the letter indicated that he had a severe reaction with the third Pfizer dose and no problems with the standard protein base booster from Novavax. https://podcasts.apple.com/us/podcast/this-week-in-virology/id300973784?i=1000759165765
1 · Reply
Benroxx
Benroxx Apr. 4 at 3:02 PM
$NVAX ChainShah
0 · Reply
Benroxx
Benroxx Apr. 4 at 3:02 PM
$NVAX Think it’s Shah
0 · Reply
Benroxx
Benroxx Apr. 4 at 3:01 PM
$NVAX One person in India is sick in his stomach right now, this is huge
0 · Reply
Biotechlineup
Biotechlineup Apr. 4 at 2:12 PM
$NVAX I’m not happy with the technical pattern, not happy with the Rux departure, not happy with the the Shah uncertainty. Not happy with Jacobs, can’t really disagree with some of the disgruntled posters to much on that. One thing that is of primary importance is the science and that remains rock solid. Sanofi and Pfizer have partnered and collaborated. My investment thesis comes down to every BP is going to want At least some access to Matrix M. Merck ofcourse the primary in need BP with two multi billion dollar franchises Gardasil and Keytruda that would benefit. Every BP could benefit. How can you not want the safest most efficacious adjuvant? So JJs words “ Don’t be surprised on a near term deal” are what we are waiting for.
1 · Reply
Biotechlineup
Biotechlineup Apr. 4 at 2:01 PM
$NVAX In case you were wondering, yes Nuvaxovid 25/26 JN.1 got you covered against circadia. The Novavax COVID-19 vaccine has a broader immune response magic m and a unique nanoparticle . Magic m provides a broadened epitope recognition, this means the immune system learns to recognize a wider variety of "shapes" (epitopes) on the spike protein rather than focusing only on a few dominant ones. Why will Nuvaxovid provide protection against BA 3.2 and mRNA will get you dead? 75 mutations, so the antibody targets gone. Nuvaxovid recognizes the less mutated regions of the spike protein. mRNA with those wonderful NAbs directed at specific areas peaks and wanes. Nuvaxovid on the other hand has magic m which induces Th1 dominant immune response that initiates a response much broader. The nano particles are also key which resemble the actual virus. The long term memory is also very important difference. More potent cd4 and cd8 + killer T cells which are less affected by surface mutations.
1 · Reply
avocadro
avocadro Apr. 4 at 1:46 PM
$NVAX Thinking that this is still a covid play is pretty silly. Covid will never save a single company. It is dead in the public’s eye.
0 · Reply
Paulchowda
Paulchowda Apr. 4 at 12:19 PM
$NVAX they sure to make a loud noise,back in the jungle in Cambodia while on a mission they sure helped Charlie as we couldn’t hear anything😜
1 · Reply
Trader00995
Trader00995 Apr. 4 at 2:11 AM
$NVAX even cicada will not move this fat ass. $7.15 on the table, thanks josh✌🏼
0 · Reply
Rask
Rask Apr. 3 at 11:51 PM
$NVAX https://www.unmc.edu/healthsecurity/transmission/2026/04/01/a-new-covid-19-variant-called-cicada-is-spreading-heres-what-to-know/#:~:text=CBS%2520News%2520%E2%80%9CCicada%E2%80%9D%2520is%2520trending,it's%2520not%2520the%2520dominant%2520strain
0 · Reply
Chelsea100
Chelsea100 Apr. 3 at 11:01 PM
$NVAX oh shit, time to fear!!! https://x.com/merlijntrader/status/2040036596737569206?s=46&t=lkQ3_6pbI_wwJJuBKrPrMw
0 · Reply
nikeita
nikeita Apr. 3 at 10:07 PM
$NVAX cicada spreading fast https://x.com/covid19_disease/status/2040127329352266104?s=46&t=5tVHMrkvvkZYxi9nUTBL0Q
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Apr. 3 at 8:04 PM
$NVAX They need to get it together and do the trial. No doubt Moderna will side-step out. This would be a political sure thing for politicians that would get back behind the double-blind placebo control trials. The whole sector will languish if this ball is fumbled. Shameful.
0 · Reply
Trissy
Trissy Apr. 3 at 6:46 PM
$NVAX In an interview, Shaw said that one of his main thrusts in life is to see his beloved homeland of India thrive. Novavax is not going to be a hostile takeover conquest to him. It is going to be a partnership between Novavax and Serum Institute of India partnering to create the FIRST CIC vaccine to market in the WORLD And possibly.. The FIRST umbrella DiSEASE X vaccine in the world This is activism investing at its finest and would result in a PEACE PRIZE
0 · Reply
Trissy
Trissy Apr. 3 at 6:38 PM
$NVAX In terms of CIC The Serum Institute of India and Novavax CIC might become the FiRST approved CIC in the world. The CDSCO just passed measures to allow for the acceleration of deployment. As a geopolitical bridge and leverage point - someone like say Shaw might see someone like say Trump seeing/using this to gain favor with India and China.
0 · Reply
Trissy
Trissy Apr. 3 at 6:23 PM
$NVAX As of late 2025, SII and Novavax are also using their validated baculovirus-based platform to target H5N1 bird flu as a prototype for potential pandemic threats (Disease X), showcasing the platform's versatility.
0 · Reply
OneDollarBob
OneDollarBob Apr. 3 at 5:43 PM
$NVAX For those who believe, thank you God for giving us the day off from watching this miserable stock. Happy Easter.
1 · Reply